ArticleBlood advances2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.Future oncology (London, England) · 2025Pooled it
- A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?Annals of hematology · 2025Pooled it
- Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review.PloS one · 2022Pooled it
- Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.Haematologica · 2023Trial
- Eprenetapopt (APR-246) and Azacitidine inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Epigenetics and In Silico Transcriptome Analysis of Pediatric Acute Myeloid Leukemia.European journal of haematology · 2026Review
- Comparing National Health Technology Assessment approaches and the new European Joint Clinical Assessment framework: The case of onco-hematological medicines.European journal of clinical pharmacology · 2026Article
- Personalized Venetoclax Dose Adjustment in Unfit Acute Myeloid Leukemia Patients: A Real-Life Case Series Study.Journal of personalized medicine · 2026Article
- Molecularly targeted therapy and immunotherapy in leukemias.Journal of hematology & oncology · 2026Review
- Immunosenescence: Shaping the Hematological Narrative in the Era of Aging.Aging and disease · 2025Review
- Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.Annals of hematology · 2025Article
- Treatment challenges and outcomes of older patients with acute myeloid leukemia from India.Annals of hematology · 2024Article
- Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019.EClinicalMedicine · 2024Article
- Generation of a new therapeutic D-peptide that induces the differentiation of acute myeloid leukemia cells through A TLR-2 signaling pathway.Cell death discovery · 2024Article
- Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece.Journal of clinical medicine · 2024Article
- Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice.Journal of personalized medicine · 2023Article
- Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.American journal of hematology · 2023Article
- The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions.Bioengineering (Basel, Switzerland) · 2023Review
- Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia.EJHaem · 2023Article
- Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.Blood · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
The hypomethylating agents (HMAs) azacitidine and decitabine have been the de facto standard of care for patients with acute myeloid leukemia (AML) who are unfit for intensive therapy. Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we identified 2263 older adults (age ≥66 years) diagnosed with AML during 2005-2015 who received a first-line HMA; 1154 (51%) received azacitidine, and 1109 (49%) received decitabine. Median survival from diagnosis was 7.1 and 8.2 months (P < .01) for azacitidine- and decitabine-treated patients, respectively. Mortality risk was higher with azacitidine vs decitabine (hazard ratio [HR], 1.11; 95% confidence interval [CI], 1.01-1.21; P = .02). The findings were similar when evaluating only patients completing ≥4 cycles (42% of patients treated with either azacitidine or decitabine). These findings lost significance when evaluating those completing a standard 7-day schedule of azacitidine (34%) vs 5-day schedule for decitabine (66%) (HR, 0.95; 95% CI, 0.83-1.08; P = .43). Red blood cell (RBC) transfusion independence (TI) was achieved in one-third of patients with no difference between the 2 HMAs. In conclusion, the majority of older AML patients did not receive the minimum of 4 cycles of HMA often needed to elicit clinical benefit. We observed no clinically meaningful differences between azacitidine- and decitabine-treated patients in their achievement of RBC TI or survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.